ChiLdhood Arthritis Risk factor Identification sTudY (CLARITY)

The aetiology of juvenile idiopathic arthritis (JIA) is largely unknown. CLARITY – ChiLdhood Arthritis Risk factor Identification sTudY, is a biobank of biological samples and questionnaire data obtained from cases of JIA and healthy control children in Melbourne, Australia.

The broad aim of the study is to identify genomic and environmental risk factors for the disease.CLARITY is a cross-sectional biobank with retrospective lifecourse data collected at time of enrolment, with the age of participants at enrolment ranging from 0 – 19 years. This data collection includes information on pregnancy and birth and biological samples from newborn (Guthrie) screening cards. Recruitment commenced in 2008 and is ongoing.

Study Summary
Study name ChiLdhood Arthritis Risk factor Identification sTudY
Study abbreviation CLARITY
Current principal investigator/s Jane Munro
Primary Institution/s Murdoch Children’s Research Institute - MCRI
Major funding source/s National Health and Medical Research Council - NHMRC
Arthritis Australia
Rebecca L. Cooper Foundation
LEW Carty Charitable Foundation
ANZ Medical Research and Technologies in Victoria
Equity Trustees Lynne Quayle Charitable Trust Fund
The Australian Academy of Science
The Victorian State Government Operational Infrastructure Support Program
Australian Research Council - ARC
Study website
Key reference for study Ellis, J.A., Ponsonby, A.L., Pezic, A., Chavez, R.A., Allen, R.C., Akikusa, J.D. and Munro, J.E. (2012). CLARITY – ChiLdhood Arthritis Risk factor Identification sTudY. Pediatr Rheumatol Online J. 10(1): 37. doi: 10.1186/1546-0096-10-37.
Study focus

CLARITY is a biobank of children with and without Juvenile Idiopathic Arthritis (JIA) established to identify genomic and environmental disease risk factors for developing JIA. CLARITY also seeks to understand the differences in the natural disease progression in children with JIA, and responses to treatments. Long term, this study will inform the development of new treatments, ideas for prevention, and better care for children living with JIA.

Sampling frame

Cases were recruited from public or private clinics at RCH diagnosed with JIA by a paediatric rheumatologist before 16 years of age.
Controls recruited from RCH Day Surgery Unit attending for minor surgical procedures.

Primary study type Databank / Biobank
Primary participant (at recruitment) Index child
Year commenced


Is this study ongoing? Yes - the study is ongoing
Ongoing recruitment? Yes
Sample size (N)

1470 (as of July 2019): 710 cases, 760 controls

Survey data available? Yes
Imaging data available? No
Linkage to administrative dataset/s? No, no consent to link to administrative dataset(s) obtained
Biosamples available? Yes
Are data available to others outside study team, with appropriate safeguards and structures in line with the cohort’s ethics and governance processes? Yes
Are there any costs associated with data/sample access for approved requests? There are usually no costs associated with access
Broadest type of participant consent available Extended consent (can be used for future ethically approved research related to this project)
Study Contacts
Principal investigator/s Jane Munro
Study Contact

Phone: (03) 8341 6251
Address: Royal Children’s Hospital
Flemington Road, Parkville
Victoria 3052 Australia